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Abstract
Introduction: Despite high rates of successful treatment TB incidence in South Africa remains high, suggesting ongoing
transmission and a large reservoir of latently infected persons. Isoniazid preventive therapy (IPT) is recommended as
preventive therapy in HIV-infected persons. However, implementation has been slow, impeded by barriers and challenges
including the fear of non-adherence.
Objective and Methods: The aim was to evaluate predictors of IPT non-completion. One hundred and sixty four
antiretroviral therapy (ART)-naı¨ve HIV-infected patients with tuberculin skin test $5 mm were recruited from Khayelitsha
day hospital and followed up monthly. A questionnaire was used to collect demographic information.
Results: The overall completion rate was 69%. In multivariable analysis, there was a 29% decrease in risk of non-completion
for every year after HIV diagnosis (OR 0.81; 95% C.I. 0.68–0.98). Self-reported alcohol drinkers (OR 4.05; 95% C.I. 1.89–9.06)
also had a four-fold higher risk of non-completion, with a strong association between alcohol drinkers and smoking (x2
27.08; p,0.001).
Conclusion: We identify patients with a recent HIV diagnosis, in addition to self-reported drinkers and smokers as being at
higher risk of non-completion of IPT. The period of time since HIV diagnosis should therefore be taken into account when
initiating IPT. Our results also suggest that smokers and alcohol drinkers should be identified and targeted for adherence
interventions when implementing IPT on a wider scale.
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Introduction
Tuberculosis (TB) represents a threat to global public health,
despite the availability of efficacious treatment, with a third of
people estimated to be latently infected worldwide, 33.2 million
with HIV infection [1]. HIV-1 (HIV) is the strongest known risk
factor for TB and where these pandemics intersect, they are the
most common cause of death among young adults in many
countries. Sub-Saharan Africa bears the brunt of this burden with
the World Health Organization (WHO) Africa region having the
highest estimated incidence rate [2].
In response to these dual epidemics, the WHO’s STOP TB
strategy to reduce the global burden of TB by 2015, recommends
collaborative HIV/TB activities including the three ‘‘I’’s for HIV/
TB: Intensified Case-Finding (ICF), Isoniazid Preventive Therapy
(IPT), and Infection Control in addition to antiretroviral therapy
(ART) [3]. IPT has been shown to significantly reduce the risk of
incident TB [4] predominantly in those with positive tuberculin
skin test. This benefit depends on good adherence to the treatment
regime. While ART roll-out has been expanding, implementation
of IPT has been slow, impeded by barriers and challenges. This
lack of implementation is in part due to fear of non-adherence [5].
South Africa is a high TB burden setting with an estimated
incidence rate in 2010 of 981/100,000, and with 60% of TB cases
occurring in HIV-infected persons [6]. This makes IPT crucial to
TB control in this high-burden setting. IPT is slowly being
implemented in the public health sector. WHO estimates of the
number of people on IPT in South Africa show an increase from
7359 in 2008 to 124,049 persons in 2010 [6,7]. However, this
represents a small fraction of people eligible to receive IPT.
Furthermore, this does not elaborate on the proportion of persons
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initiating IPT that complete the course. Literature on adherence to
IPT from higher-income settings have shown varying IPT
completion rates from 45% in the USA [8] to 81% in Spain [9].
Factors identified to be associated with non-adherence, including
younger populations, males, smokers and recent migrants, have
also been shown to vary across different population groups [8–12].
This highlights a need for local data on completion rates and
predictors of non-completion of IPT amongst eligible persons.
We report on completion rates of IPT within a research context
and patient-related predictors of non-completion as a means of
identifying those at high risk of non-adherence.
Methods
Study Design, Setting and Population
Participants in this study were identified from a larger cross-
sectional TB diagnostics study to develop biomarkers that
distinguish active from latent TB and other infections. The study
was conducted at site B Day Hospital, a primary care health
facility in the informal township of Khayelitsha. Located 30 km
from Cape Town, Khayelitsha has a population of over 400,000
and a TB case notification rate of over 1600/100 000, 70% of
which occur in HIV co-infected persons [13].
Ethics Statement
Written informed consent was obtained from all participants
recruited as part of a larger TB diagnostics study. This study was
approved by the University of Cape Town health research ethics
committee (REC 012/2007).
Sampling and Recruitment Strategy
Study participants were recruited from the HIV wellness clinic,
comprising patients not eligible for antiretroviral therapy (ART) at
Khayelitsha day hospital, between February 2008 and March
2010. Participants were ART-naive with CD4$200 cells/mm3,
either newly diagnosed or attending for minor ailments. Consec-
utive patients attending the clinic without any symptoms of TB
were invited to participate, tested for evidence of latent TB and
screened for active TB using a symptom screen, sputum
microscopy and culture and chest radiography. Latent TB (LTBI)
was diagnosed in these HIV-infected persons by the tuberculin
skin test (TST) using 2 TU of tuberculin PPD RT23 injected
intradermally into the volar aspect of the forearm and read 48–72
hours later by a dedicated study nurse. A transverse induration
diameter $5 mm was considered as evidence of LTBI. Partici-
pants were considered alcohol drinkers if they reported regular
alcohol consumption. Smokers were defined as participants who
self reported current smoking and non-smokers as never- or ex-
smokers.
Asymptomatic persons identified with a skin induration
diameter of $5 mm and no evidence of active TB disease were
given information about the implications of infection with latent
TB infection and the risk of progression to active TB, and
commenced on IPT for six months, as per South African national
guidelines. Participants were seen at monthly visits to monitor
adherence and side effects, and the benefit of IPT in HIV-infected
persons and importance of completion of the course reinforced by
the study investigator at every visit. Adherence was measured by
self-reported adherence on attendance of follow-up appointments.
The same investigator ascertained self-reported adherence at these
visits by asking patients if they took the pills as prescribed everyday
in the preceding month. Patients who missed an appointment
received a daily telephonic reminder and failing that after a week,
a home visit by the trained clinical research assistant to encourage
clinic attendance. As IPT was dispensed at monthly follow-up
visits, non-completion of IPT (outcome variable) was defined as a
failure to attend all six monthly appointments within a nine-month
period.
In addition, a questionnaire, applied by trained study personnel,
was used to collect baseline demographic information including
age, employment status, alcohol consumption, smoking status, past
TB history, recent TB contact, type of accommodation lived in,
and date of HIV diagnosis. This questionnaire was designed for
the larger TB diagnostics study and data for this study extracted
from the database. No study incentives were provided to
participants. We hypothesized, based on existing literature, that
male sex, being employed, consuming alcohol and smoking would
be predictors of non-completion of IPT.
Statistical Analysis
Patient baseline characteristics were stratified by outcome and
summarised using simple proportions. Predictors of non-comple-
tion were analysed by logistic regression and nested models
compared using the likelihood ratio test. The Chi squared test was
used to compare proportions. The Akaike’s Information Criterion
(AIC) was used to compare non-nested models with a lower AIC
indicating a better model. The interactions between confounding
and exposure variables were then examined. The fit of the model
was assessed using Pearson’s goodness-of-fit test with a p-value
.0.05 indicating a good fit. Model diagnostics were performed on
final models by checking the form of the linear predictors.
Significance testing was done using two-sided p-values and 95%
confidence intervals. All data were analysed using STATA 10.0
(StataCorp, College Station, TX, USA).
Results
Baseline Characteristics and IPT Completion Rate
Of the three hundred and fifty three asymptomatic participants
screened, one hundred and sixty four participants identified with
LTBI were initiated on IPT (Figure 1). Overall, one hundred and
thirteen persons (69%) completed the six-month IPT course within
a nine-month period. Participants that attended all appointments
and completed the six-month course reported taking dispensed
pills from the preceding month as prescribed.
Baseline characteristics were compared, stratified by completion
or non-completion of a six-month course of IPT, and summarized
in Table 1. Amongst those that did not complete the IPT course, a
median of two months IPT (IQR 0–3 months) was completed.
Compared to those who completed IPT, patients who did not
complete the course had a higher proportion of smokers (21.6%
versus 9.7%; p = 0.04) and alcohol drinkers (37.2% versus 14.2%;
p = 0.001). They were more likely to have been recently diagnosed
with HIV (median time since HIV diagnosis 54 days (IQR 6–910)
Figure 1. Flow diagram of screening and enrolment into study.
doi:10.1371/journal.pone.0052489.g001
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versus 421 days (IQR 43–1479); p = 0.002). There were also a
higher proportion of men versus women (22.4% versus 15%;
p = 0.252) in the non-completers group, although not statistically
significant. Similarly, a greater proportion of non-completers were
recent migrants to Khayelitsha (11.9% versus 5.3%; p = 0.155)
although numbers were small. The distribution of all other
measured baseline characteristics were similar between the two
groups.
Predictors of Non-completion of IPT
On univariable analysis, being male, smoking, alcohol, and a
recent HIV diagnosis were associated with an increased risk of IPT
non-completion (Table 1). There was a significant association
between being male and drinking alcohol (p = 0.002) and smoking
(p,0.001). There was also a strong association between smoking
and drinking (p,0.001).
On multivariable analysis the final logistic regression model
included alcohol and time since HIV diagnosis variables only.
There was a 19% decrease in odds of non-completion with every
year after HIV diagnosis (OR 0.81; 95% C.I. 0.68–0.98; p = 0.03)
and a four-fold increase in odds of non-completion in drinkers
compared to non-drinkers (OR 4.05; 95% C.I. 1.89–9.06;
p = 0.001).
Due to the strong association between smoking and drinking we
chose to include the alcohol variable, as its inclusion in the model
resulted in a marginally better fit of the model to the data using the
Pearson goodness of fit test compared to a model that included
smoking. However, given the association between these two
variables, both should be considered in the interpretation of these
results. There was no significant effect modification between
gender and drinking or smoking although it should be noted that a
greater proportion of male versus female participants reported
being smokers (46% versus 7%) and drinkers (43% versus 16%).
We further explored the relationship between the period of time
since HIV diagnosis and non-completion of IPT by examining the
proportion of non-completers stratified into four time periods since
HIV diagnosis (,6 months, 6–12 months, 1–5 years, and.5 years
since HIV diagnosis). Figure 2 shows that non-completers were
most likely to default IPT if initiated within six months of HIV
diagnosis compared to persons initiated after at least six months
post-HIV diagnosis (p = 0.006).
Discussion
We report a 69% IPT completion rate in this ART-naı¨ve HIV-
infected population in Cape Town suggesting that adherence in
this setting is a potential major challenge to achieving full benefit
from this public health intervention. Furthermore we found that
non-completion of IPT was associated with a recent HIV diagnosis
and alcohol use. Studies conducted in similar high burden settings
have reported IPT completion rates from 47% in HIV-infected
adults attending clinics in Limpopo, rural South Africa to 78% in
participants involved in a randomized controlled trial in Botswana
[14,15].
These results highlight a need for innovative strategies to
improve adherence and recent studies have explored interventions
using cellular telecommunication networks and mobile phones
[16].
Studies examining risk factors for non-completion have reported
male patients as being at risk of non-completion [15,17] with men
being twice as likely to be non-completers and women being three
times as likely as men to complete the course, respectively. We
explored quantitative patient predictors of non-completion of IPT
and our results were coherent with existing literature [11,18], with
alcohol drinking and smoking found to significantly increase the
risk of non-completion. In this high-burden setting, this association
possibly relates to marginalization representing a social risk factor.









Gender Female 96 (85.0) 39 (76.5) 2.34 (0.97–5.64)
Marital status Married 33 (29.2) 10 (19.6) 0.93 (0.40–2.14)
Smoker Yes 11 (9.7) 11 (21.6) 3.59 (1.41–9.18)
Alcohol Yes 16 (14.2) 19 (37.2) 4.66 (2.03–10.69)
TB contact No Yes Don’t know 78 (69.0) 30 (26.6) 5 (4.4) 41 (80.4) 10 (19.6) 0 (0.0) 0.54 (0.23–1.26)
Previous TB Yes 15 (13.3) 6 (11.8) 0.94 (0.32–2.79)
BCG Scar Yes 62 (54.9) 23 (45.1) 0.92 (0.44–1.94)
Self–reported BCG No Yes Don’t know 19 (16.8) 80 (70.8) 14 (12.4) 11 (21.6) 33 (64.7) 7 (13.7) 1.13 (0.58–2.22)
Employed Yes 41 (36.6) 17 (33.3) 0.85 (0.39–1.84)
Accommodation Shack House 66 (58.4) 47 (41.6) 21 (50.0) 21 (50.0) 1.46 (0.69–3.06)
Time in Khayelitsha ,1 year .=1 year 6 (5.3) 107 (94.7) 5 (11.9) 37 (88.1) 0.39 (0.11–1.36)
Characteristics Median (IQR) Median (IQR) OR (95% C.I.)
Age (years) 32.7 (27.4–37.8) 29.8 (24.5–35.9) 0.99 (0.94–1.04)
BMI 27.2 (22.8–31.6) 24.2 (21.3–30.5) 0.96 (0.90–1.02)
Education Highest school grade achieved 11 (9–12) 11 (10–12) 1.07 (0.90–1.29)
Persons/bedroom 2.33 (1.67–3) 2 (2–3) 0.91 (0.68–1.20)
CD4 count (cells/mm3) 360 (269–508) 363 (261–526) 1.00 (1.00–1.00)
Years since HIV diagnosis 1.15 (0.12–4.05) 0.15 (0.02–2.49) 0.82 (0.67–0.99)
doi:10.1371/journal.pone.0052489.t001
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This was demonstrated by a study in Spain that reported an
association between non-adherence and patients with unfavour-
able social circumstances such as alcohol and drug abuse and
recent immigrants [9].
In addition, we also found patients with a more recent HIV
diagnosis had a higher risk of non-completion. This could relate to
non-acceptance of HIV status and a resulting reluctance to attend
follow-up appointments. It could also relate to non-disclosure of
HIV status to friends and family and wanting to keep their HIV
status confidential, resulting in an unwillingness to attend the
health facility. In addition, this finding could be related to their
perceived risk and lack of education on HIV opportunistic
infections such as TB, information often received at HIV clinics.
A study conducted in Thailand reported acceptance of personal
HIV status as a predictor of adherence [17]. Patients established in
HIV clinics are potentially more likely to have accepted their HIV
status and therefore more likely to have developed a habit of
attending the health facility for routine appointments and for
minor ailments, which could facilitate IPT adherence. However,
barriers such as transport costs to the health facility and a
reluctance to take medication when feeling healthy could impact
adherence even among patients established in care. Our study did
not assess reasons for the association and these potential reasons
for non-completion of therapy should be investigated in further
study. Based on these findings, it is possible that provision of
comprehensive counseling to patients with a recent HIV diagnosis,
as offered prior to ART initiation, may lead to better acceptance of
HIV status and good adherence to IPT.
Studies in high-income settings have demonstrated that
provision of shorter LTBI regimens under research [19] is
associated with better adherence [20]. Therefore it is possible
that new shorter regimens could significantly improve adherence
and completion rates.
Based on existing literature, we hypothesized that male and
unemployed patients would also be at higher risk of non-
completion. Unemployment rates are high in Khayelitsha and
this could explain why employment was not associated with
adherence in our study. Sixty-five percent of drinkers and 59% of
smokers were male suggesting that the expected association
between male sex and non-completion of IPT could relate to a
greater proportion of alcohol drinkers and smokers within this
group and could explain why being male was not a significant risk
factor in this study.
Limitations
Although IPT follow-up was conducted within the health
facility, it was conducted within a research context and it is likely
that adherence in operational settings will be lower than in a
research study. Our measurement of completion was IPT was
based on self-reported adherence, which may overestimate the
proportion of completers. However, all participants that reported
good adherence attended all six monthly visits, suggesting good
self-motivation and making it more likely that they completed the
IPT course. Substance abuse, commonly reported in this
community and a possible risk factor for non-completion to be
considered in the wider implementation of IPT, was not measured
in this study. The quantity and frequency of alcohol use was not
recorded and it is possible that the association between non-
adherence and alcohol use is restricted to excessive or binge
drinking. Healthcare worker related barriers to IPT implementa-
tion were identified by Getahun et al, with lack of experience and
knowledge of current guidelines cited as an important barrier [7].
Another barrier to implementation identified includes fear of side
effects with hepatitis and peripheral neuropathy most common
[17,21]. Our study did not examine the impact of healthcare
worker related barriers or IPT side effects on adherence.
Conclusions
The WHO has identified IPT as one of the main interventions
to reduce morbidity and mortality from TB in people living with
HIV. A better understanding of predictors on non-adherence to
IPT is therefore crucial to optimize adherence in high HIV/TB
burden settings. Implementation of IPT has been slow in South
Africa. The findings of this study are therefore important as the
completion rate reported demonstrates the potential feasibility of
providing IPT in this setting.
Figure 2. Histogram showing the proportion of IPT non-completers stratified by time period since HIV diagnosis. N represents the
total sample size of participants in each time period.
doi:10.1371/journal.pone.0052489.g002
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Retention of pre-ART patients in care is often challenging.
Provision of IPT, as part of a package of care including counseling
and cotrimoxazole prophylaxis, could therefore provide a means
of improving retention in care, especially for patients recently
diagnosed with HIV.
The identification of a recent HIV diagnosis as a significant
predictor of non-completion suggests that in this setting, better
strategies and interventions will be required to improve adherence
to IPT in recently diagnosed HIV-infected persons. Our results
also suggest that when initiating IPT in this setting, the smoking
and alcohol history of patients should be ascertained, with targeted
adherence interventions implemented aimed at those who smoke
or drink in addition those with a more recent HIV diagnosis.
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